Navigation Links
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
Date:3/22/2013

HAYWARD, Calif., March 22, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced its abstract entitled "Blisibimod, an Emerging Subcutaneous Biologic Therapy for Patients with Active, Moderate-to-Severe Systemic Lupus Erythematosus," has been selected as an oral presentation and will be presented at the 10th International Congress on Systemic Lupus Erythematosus by Dr. Morton Scheinberg , a rheumatologist at the Hospital Abreu Sodre Pesquisa Clinica in Sao Paulo, Brazil, on April 20, 2013.

Additionally, a poster entitled "Clinical Experience in Latin America With Blisibimod Amongst Subjects with Active, Moderate-to-Severe Systemic Lupus Erythematosus: Data From The Phase 2b PEARL-SC Study," will be presented by Dr. Scheinberg as part of the conferences Guided Poster Tours on April 19, 2013.

The poster will be available on www.anthera.com.

About Blisibimod and PEARL-SC

BAFF has been associated with a wide range of B-cell-mediated autoimmune diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy, immune thrombocytopenic purpura and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF inhibitors potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a selective inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications.  The PEARL-SC Phase 2 study was designed as a ran
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
2. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
3. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
9. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
10. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Alimera Sciences, Inc. ... that specializes in the research, development and commercialization of ... its second quarter of fiscal year 2014 financial results ... An investor conference call will follow on the same ... conference call will be hosted by Dan Myers ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
(Date:7/24/2014)... 24, 2014  Perrigo Company (NYSE: PRGO ... AB therapeutic equivalent rating from the U.S. Food and ... Application (NDA) for testosterone gel 1.0%. FDA concluded that ... 1% and can be substituted with the full expectation ... safety profile as AndroGel 1% when used under the ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter 2014 Results 2LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... evaluate, clinical utility of protein biomarkers for predicting treatment ... ... Conn., Sept. 4 HistoRx, Inc., announced,today that it has ... (RTOG), a National Cancer Institute-funded clinical,cooperative group. Under the terms ...
... - ViziLite Plus with TBlue630 -, PHOENIX, Sept. ... with Tblue630(TM) screening system for early detection of,abnormalities which ... identify,pre-cancerous lesions in a Phase II study of Cetuximab ... developed by ImClone,Systems (Nasdaq: IMCL ) and distributed ...
Cached Medicine Technology:HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 2HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership 3Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 2Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX 3
(Date:7/24/2014)... shows that incisionless transcatheter aortic valve replacement (TAVR) ... percent and has no impact on post-operative vascular ... which requires an incision in the groin. The ... of Circulation: Cardiovascular Interventions . , TAVR ... a traditional open-heart surgical approach. It is a ...
(Date:7/24/2014)... M.D., director of The Miriam Hospital,s HIV/Viral Hepatitis ... Rhode Island Medical Journal special edition, "RI ... infection (hep c or HCV) is feasible, can ... health challenges, and improve health care disparities. Barriers ... says, include lack of funding earmarked for HCV ...
(Date:7/24/2014)... Angeles, CA (PRWEB) July 24, 2014 On ... loved ones will descend upon the Embassy Suites LAX North ... Conference hosted by DiabetesSisters and the first time it has ... first time for the organization to open the entire event ... As the only conference of its kind worldwide for women ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... Optometric Association (AOA) and the Entertainment Industries Council ... the TV series American Horror Story on a ... bring the dramatic realities of illegal and unsafe ... campaign, which has already reached tens-of-thousands, is now ...
(Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- Human semen is ... microbes might have a role to play in both HIV ... that bacteria in semen -- the "microbiome" -- play a ... by infected men. They say the findings point to possible ... study couldn,t prove that the bacteria was causing changes in ...
Breaking Medicine News(10 mins):Health News:Penn study: Incisionless transcatheter aortic valve replacement surgery cuts hospital length of stay 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 2Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:Bacteria in Semen May Affect HIV Transmission, Levels: Study 2
... 19th century, Jean-Martin Charcot, the celebrated neurologist, developed a ... reported improvements in his patients, but he died shortly ... was never conducted. Now, a group of neurological ... work in a study to see if Charcot,s observation ...
... the more than 36 million people plagued by tinnitus, ... worsening the functional and emotional toll of chronic ringing, ... according to a new study from Henry Ford Hospital ... between insomnia and the severity of perceived tinnitus symptoms, ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, April ... Wednesday issued the first national standards to curb air pollution ... to hydraulic fracturing, a way to obtain natural gas by ... release gas. Natural gas is being touted by ...
... two years later, Sarah Clark grimaces sheepishly and insists she ... "I was woefully unprepared," says Clark, a researcher ... Skyline High School in Ann Arbor. "I did not do ... math homework that night. I sent him to school the ...
... , This press release is available in ... conducted with thousands of local teenagers by University of ... or ecstasy (MDMA) at fifteen or sixteen years of ... symptoms the following year. "Our findings are consistent with ...
... Lisa Esposito HealthDay Reporter , WEDNESDAY, April 18 ... a specific number of fights and years in the ring ... head without brain damage, a new study suggests. But, ... show. "The brain can tolerate or absorb a ...
Cached Medicine News:Health News:19th century therapy for Parkinson's disease may help patients today 2Health News:Study: Insomnia takes toll on tinnitus patients 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 3Health News:Football helmet sensors help researchers demystify concussion in young athletes 2Health News:Speed and ecstasy associated with depression in teenagers 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 3
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
Indirect hemagglutination test for the qualitative and quantitative determination of antibodies to Toxoplasma gondii in serum....
... Rapid Plasma Reagin ... rapid detection and quantitative ... serum or plasma. Uses ... to detect reagin. Kits ...
Latex agglutination slide test for the qualitative and quantitative detection of rubella virus antibody in serum....
Medicine Products: